Suppr超能文献

眶周和睑前肉毒毒素注射联合治疗反应不佳的眼睑痉挛。

The combined treatment with orbital and pretarsal botulinum toxin injections in the management of poorly responsive blepharospasm.

机构信息

Department of Neurological Sciences, University Federico II of Naples, Via Sergio Pansini, 5, 80131, Naples, Italy,

出版信息

Neurol Sci. 2014 Mar;35(3):397-400. doi: 10.1007/s10072-013-1526-2. Epub 2013 Aug 15.

Abstract

Blepharospasm (BS) is a focal dystonia involving involuntary contractions of muscles around the eyes. Botulinum toxin (BoNT) is the most effective treatment for BS and the technique of injection changes depending on the clinical picture. Usually typical BS benefits from the injection in the orbital part of the orbicularis oculi (OOc) muscle (orbital injection), while BoNT injection in the pretarsal part of OOc muscle is helpful especially for the atypical BS (opening eyelid apraxia). The aim of this study was to compare the efficacy of two injection techniques, the orbital versus the combined (injection in both orbital and pretarsal part of OOc) in BS patients with unsatisfactory response to BoNT. Nineteen patients with typical BS not having a satisfactory response from BoNT treatment with the orbital injection (primary and secondary resistant patients) were studied. After 3 months from the last orbital injection patients received the combined injection; they were assessed with the JRS and BSDI scales after 4 weeks from the last orbital and the first combined injection. Statistical analysis showed a significant reduction (p < 0.05) of the mean score of JRS and BSDI scales comparing the combined with orbital injection. This study shows that the treatment of typical BS can have better results when BoNT is injected with the combined technique in primary and secondary resistant patients.

摘要

眼睑痉挛(BS)是一种局灶性肌张力障碍,涉及眼睛周围肌肉的不自主收缩。肉毒毒素(BoNT)是治疗 BS 的最有效方法,注射技术因临床表现而异。通常,典型的 BS 从眼轮匝肌(OOc)眶部注射中获益(眶部注射),而 OOc 肌肉的睑前部分注射对非典型 BS(睁眼运动不能)特别有帮助。本研究旨在比较两种注射技术的疗效,即眶部与联合(眶部和 OOc 肌肉的睑前部分联合注射)在对 BoNT 治疗反应不佳的 BS 患者中的疗效。研究了 19 名对 BoNT 眶部注射治疗反应不佳的典型 BS 患者(原发性和继发性抵抗患者)。在最后一次眶部注射后 3 个月,患者接受了联合注射;在最后一次眶部和第一次联合注射后 4 周,他们分别接受了 JRS 和 BSDI 量表评估。统计分析显示,与眶部注射相比,联合注射的 JRS 和 BSDI 量表评分显著降低(p<0.05)。这项研究表明,在原发性和继发性抵抗患者中,BoNT 联合注射技术可使典型 BS 的治疗效果更好。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验